The measurement of 1,25(OH) 2 D presents several analytical challenges. The compound circulates at picomole per liter concentrations and is highly lipophilic. Furthermore, the structurally similar metabolic precursor 25(OH)D circulates at nanomole per liter concentrations, making assay specificity a constant analytical concern. Measurement of 1,25(OH) 2 D has undergone many improvements (2 ) . A radioreceptor assay (RRA) based on the competitive binding of 1,25(OH) 2 D and tritiated tracer to its nuclear receptor isolated from calf thymus was introduced in the mid-1980s (3 ). The calf-thymus receptor assay is attractive because it involves purification and binding to the natural receptor for 1,25(OH) 2 D and adjustment for recovery. Commercial methods for 1,25(OH) 2 D do not adjust for recovery, and they involve the use of antibodies. Our laboratory has continued to use the calf-thymus receptor method, and is 1 of the last 2 laboratories reporting data with the method to the Vitamin D External Quality Assurance Scheme (DEQAS). Most clinical laboratories who offer 1,25(OH) 2 D assays use commercially available methods (4 ) . Currently, the most commonly used methods for 1,25(OH) 2 D quantification are competitive RIAs using a 125 I tracer. The methods involve extraction, but they do not adjust for between-sample variation in extraction efficiency. Two commercially available assays sold by DiaSorin and IDS dominate the market. They primarily differ in their respective 1,25(OH) 2 D extraction methods before assay and in sensitivity to 1,25(OH) 2 D 2. The DiaSorin method uses a solid-phase extraction and silica purification using organic solvents (acetonitrile, methanol, methylene chloride, hexane, and isopropanol) while the IDS method employs a solid phase immunoextraction, avoiding organic solvents, but involving overnight incubation and a 2-day assay procedure. For the 1,25(OH) 2 D 2 metabolite, the DiaSorin and IDS RIA methods state 100% and 91% specificity, respectively.
A new enzyme immunoassay (EIA) for the measurement of 1,25(OH) 2 D uses solid-phase immunoextraction and colorimetric detection. The manufacturer's claim that this method has only 39% reactivity of 1,25(OH) 2 D 2 compared with 1,25(OH) 2 D 3 is a concern because vitamin D 2 is commonly used clinically. We present our data for comparison of the EIA to our in-house RRA, as well as an evaluation of lot-to-lot calibration stability and potential compliance with external proficiency surveys.
Materials and Methods thymus rra
Calf-thymus receptor assay, involving purification of analyte on Bond Elut C18OH cartridges (Varian) and an internal tritiated calibrator to correct for losses during purification, has been described (5 ) . Instead of an antibody, this method is based on competition for the nuclear 1,25(OH) 2 D receptor extracted from calf thymus.
ids eia
Reagent sets were donated by IDS Ltd., and we followed manufacturer instructions. We delipidated samples with dextran sulfate and magnesium chloride solution, centrifuged them to pellet debris, and extracted analytes using immunocapsules (100 L sample/capsule, assayed in duplicate) containing monoclonal antibody to 1,25(OH) 2 D linked to solid-phase particles in suspension with vitamin D binding protein inhibitor. Immunocapsules were agitated on a rocker-shaker for 90 min at room temperature (18 to 25°C), washed 3 times with deionized water, and extracted analyte was eluted with 3 successive applications of 150 L ethanol. Eluates were evaporated under a gentle flow of nitrogen or by SpeedVac evaporator (Savant). We reconstituted calibrators (lyophilized BSAphosphate buffer containing 1,25(OH) 2 D and 0.9 g/L sodium azide) immediately before assay or thawed them from frozen. Dry, immunopurified samples were resuspended with assay buffer (BSA-phosphate buffer with 0.9 g/L sodium azide). We added primary antibody solution (sheep anti-1,25(OH) 2 D in BSA-phosphate buffer with 0.9 g/L sodium azide) to all tubes, and they were incubated overnight (16 -20 h) at 2-8°C. The next day, we applied samples to appropriate wells of the antisheep IgG-linked 96-well microplate. We selected the plate layout to minimize sample positional bias. Calibrators were run in duplicate and placed on opposite ends of the plate.
Controls were run in duplicate on half plates and in quadruplicate on full plates and placed on the ends and middle of the plate. All samples were placed so that no replicate was ever placed in an immediately adjoining well. The plate was incubated on an orbital shaker at 18 -25°C for 90 min, then 1,25(OH) 2 D biotin solution was added to all wells except the substrate blanks, and the plate was incubated on an orbital shaker (500 -750 rpm) at 18 -25°C for 60 min. We washed the plate 3 times, added avidin linked to horseradish peroxidase to all wells except the substrate blanks, and incubated the plate at 18 -25°C for 30 min. We repeated the washes and added tetramethylbenzidine substrate to all wells including the substrate blanks. The reaction was developed at 18 -25°C for 30 min and stopped with 0.5 mol/L hydrochloric acid. Plates were read at 450 nm (reference 630 nm) using a microplate reader within 30 min of adding the HCl solution.
We calculated percentage binding (B/B 0 ) of each calibrator, control, and unknown sample as (mean absorbance Ϫ mean absorbance substrate blank) ϫ 100/(mean absorbance for 0 calibrator Ϫ mean absorbance substrate blank). We prepared a calibration curve by plotting B/B 0 % on the ordinate against log concentration of 1,25(OH) 2 D on the abscissa. We fitted a 4-parameter logistic model to the curve and interpolated sample data using GraphPad software.
samples Serum samples (n ϭ 145) for method comparison were previously assayed by thymus RRA in our laboratory and selected to represent an even distribution of typical (40 -140 pmol/L), low (Ͻ40 pmol/L), and high (Ͼ140 pmol/L) concentrations. We included 5 QC samples in each run (Table 1 ) and pooled both patient material routinely used for QC with the in-house thymus RRA and the QC material from the manufacturer (lyophilized human serum containing 1,25(OH) 2 D and 0.9 g/L sodium azide). DEQAS survey samples included tubes 141-155 from the 2004 survey year. All samples were stored at Ϫ20°C between runs, and freeze-thaw cycles were minimized.
statistical analyses
All statistical analyses were performed using GraphPad Prism software. To compare different lines (Figs. 1 and 2) , we plotted the data as appropriate and determined sta- tistical differences between lines or curves by F-test on the residuals of data points around the calculated line or curve. We determined the limit of detection by triplicate extraction and measurement of 4 serial 2-fold dilutions using patient pool material at low concentration (i.e., Ͻ20 pmol/L). We calculated the limit of detection, defined as the upper 95% CI for values at theoretical 0 concentration, based on the SD of residuals (S y͉x ).
Results
Method comparison by Deming linear regression of the EIA and thymus RRA methods yielded slope 1.25 (95% CI 1.13-1.37), y-intercept Ϫ3 (95% CI Ϫ18 to 12), R 2 ϭ 0.74 (Fig. 1A) . We were initially supplied with 1 lot of EIA reagent, which was divided into 2 runs and showed promising correlation with the thymus RRA method: slope 1.57 (95% CI 1.28 -1.86), y-intercept 0.4 (95% CI Ϫ30 to 31), R 2 ϭ 0.84 (Fig. 1B) . With a 2nd lot of EIA reagents, however, results for in-house QC material values were lower, also corresponding to a significant shift in the slope vs the RRA: slope 1.19 (95% CI 1.07-1.31), y-intercept 0.4 (95% CI Ϫ20 to 11), R 2 ϭ 0.75 (Fig. 1B) . Troubleshooting efforts eliminated factors such as mixing/reconstitution problems and variability from different drying techniques (SpeedVac concentrator vs nitrogen stream) and ultimately revealed a shift in calibration when calibrators from different lots were run side-by-side on the same plate. The manufacturer subsequently informed us that they had changed their calibration between lots; the curve fits in Fig. 2 demonstrate the curve shift. Additionally, we calculated patient data collected from the same plate using both calibration curves, and paired t-test demonstrated a significant shift in sample values (P Ͻ0.0001).
We measured imprecision with 5 QC samples in quadruplicate in each run (n ϭ 6), including both pooled patient material used for QC with the RRA and QC material included with the EIA reagent set. Samples were analyzed once by RRA and twice by EIA in duplicate on the same plate. Duplicates for the EIA method were divided at the time of extraction, as opposed to pipetting duplicate wells from the same sample tube as is commonly used with ELISA techniques not requiring an extraction step. Imprecision (CV) values were 12%-16% within-run and 15%-20% between-run ( Table 1) . The cumulative distribution of between-replicate variation (Fig. 3A) demonstrated a median between-replicate CV of 3.7% (25th percentile 1.8%, 75th percentile 7.3%, 95th percentile 18.6%). The distribution of between-replicate variation as a function of analyte concentration (Fig. 3B) demonstrates that variability is minimized within the reference interval for 1,25(OH) 2 D (40 -140 pmol/L). To calculate the relative contribution of extraction and EIA to the variability of the method, we repeated analysis of between-replicate variation using calibrators from each run (data not shown). Assuming that total error can be expressed as 2 total ϭ 2 extraction ϩ 2 EIA , and that we measure total error at mean between-replicate CV, then the total error would be Ϯ5.9%, the EIA assay error would be Ϯ2.4%, and the extraction error would be Ϯ5.4%. Thus, the extraction procedure contributes significantly more to the between-replicate error than the detection protocol of the EIA itself. Calibrators from both lots were analyzed in parallel on the same plate in the same run. Data are plotted using a 4-parameter logistic curve fit. The curves are significantly different (F-test, P ϭ 0.0135).
The limit of detection, defined as the upper 95% CI for values at theoretical 0 concentration, was determined by use of replicates of extractions at low concentration. The S y x value was 4.7 nmol/L. Thus, the limit of detection was 9.4 pmol/L, consistent with our practice of reporting low values as Ͻ10 pmol/L. (Fig. 4, B-D) . EIA performance would be expected to improve if duplicates had been measured, although most laboratories routinely report clinical results based on singleton measurement.
Discussion
The IDS EIA and our in-house thymus RRA compare well with other reports about the performance of 1,25(OH) 2 D assays (6 -9 ) . Although between-run imprecision seems high in the general context of clinical chemistry, it is equally within expected performance characteristics of assays of this analyte. While we observed between-run CVs of 15%-20% in our evaluation, historical DEQAS data show that other methods are unlikely to provide better performance. Between-laboratory CVs in the 2004 DEQAS report were as follows: IDS RIA 11%-26%, Diasorin RIA 12%-30%, and overall between-method 15%-28%. The relative imprecision of this assay in general can in large part be attributed picomolar concentrations of analyte. However, we found that the extraction contributes more variability than the immunoassay component of the procedure.
The shift in calibration was discussed with the IDS technical staff, and they have made assurances that this observation was attributable to an early preproduction lot of reagents being distributed to us for evaluation. Nevertheless, it would be prudent for users to approach lot changes cautiously. This issue may be of less concern for laboratories that intend to use a predetermined number of reagent sets for clinical trials that have a defined number of patients and may not require the long-term analytical stability of a clinical service laboratory. In those cases, reagents from a single lot for a given trial would be optimal. It should be noted that calibrators are not extracted in the EIA method or the RRA method, but the RRA method uses a tracer for monitoring extraction efficiency whereas the EIA method has no such adjustment. This process would putatively make the EIA method more difficult to troubleshoot should there be a discrepancy between lots, as it would have to be determined initially if the problem was with extraction or with calibration.
According to 2003 DEQAS participation data (4 ), 59% of participants currently use the IDS RIA method for 1,25(OH) 2 D, which uses the identical immunoextraction method. Equally, the IDS RIA method for 1,25(OH) 2 D does not include calibrator extraction as part of the protocol. These results indicate that the laboratories currently using the IDS RIA and wishing to switch to a nonradioactive method could do so with relative ease. Our evaluation demonstrates that the IDS EIA would easily meet the DEQAS goal of 80% of survey samples within 30% of the all-methods mean (Fig. 4) .
In theory, the IDS EIA may underestimate 1,25(OH) 2 D 2 ; however, our data using clinical samples reveal no evidence of inferiority to the classic calf-thymus receptor assay for 1,25(OH) 2 D, and no disadvantage in the results generated by the IDS EIA using samples from the major proficiency survey for 1,25(OH) 2 D.
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